Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRITE data on BV beyond progression (BBP)

被引：1
|
作者：
Cohn, A. L.
Bekaii-Saab, T.
Bendell, J. C.
Hurwitz, H.
Kozloff, M.
Roach, N.
Tezcan, H.
Feng, S.
Sing, A.
Grothey, A.
机构：
[1] Rocky Mt Canc Ctr, Denver, CO USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Ingalls Hosp, Harvey, IL USA
[6] Univ Chicago, Harvey, IL USA
[7] C3, Alexandria, VA USA
[8] North Idaho Canc Ctr, Coeur Dalene, ID USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3596
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CLINICAL OUTCOMES IN BEVACIZUMAB-TREATED PATIENTS WITH METASTATIC COLORECTAL CANCER: RESULTS FROM ARIES OBSERVATIONAL COHORT STUDY AND CONFIRMATION OF BRITE DATA ON BEVACIZUMAB BEYOND PROGRESSION
    Cohn, A.
    Bekaii-Saab, T.
    Bendell, J.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 11 - 11
  • [2] Effectiveness of bevacizumab (BV) beyond disease progression in metastatic colorectal cancer (mCRC): Analyses by sex in the ARIES observational cohort study (OCS)
    Cohn, Allen Lee
    Hurwitz, Herbert
    Bekaii-Saab, Tanios S.
    Bendell, Johanna C.
    Kozloff, Mark
    Tezcan, Haluk
    Flick, Elizabeth Dawn
    Mun, Yong
    Fish, Susan
    Dalal, Darshan
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [3] Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (CS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)
    Grothey, A.
    Sugrue, M.
    Hedrick, E.
    Purdie, D.
    Chiruvolu, P.
    Dong, W.
    Sargent, D.
    Kozioff, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 241 - 242
  • [4] Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)
    Grothey, A.
    Sugrue, M.
    Hedrick, E.
    Purdie, D.
    Yi, J.
    Dong, W.
    Kozloff, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a bevacizumab (BV) observational study.
    Bendell, J. C.
    Bekaii-Saab, T. S.
    Cohn, A. L.
    Hurwitz, H.
    Kozloff, M.
    Tezcan, H.
    Feng, S.
    Flick, E. D.
    Sing, A.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [6] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study
    Kozloff, M. F.
    Sugrue, M. M.
    Purdie, D. M.
    Berlin, J. D.
    Flynn, P. J.
    Kabbinavar, F. F.
    Sargent, D. J.
    Dong, W.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Characteristics of long-versus short-surviving patients (Pts): An analysis of the ARIES Observational Cohort Study (OCS) of bevacizumab (BV)-treated pts with metastatic colorectal cancer (mCRC).
    Kozloff, Mark
    Grothey, Axel
    Bendell, Johanna C.
    Cohn, Allen Lee
    Bekaii-Saab, Tanios S.
    Roach, Nancy
    Flick, Elizabeth Dawn
    Mun, Yong
    Fish, Susan Meredith
    Laeufle, Rita
    Sommer, Nicolas
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS)
    Sugrue, M. M.
    Purdie, D. M.
    Feng, S.
    Flynn, P. J.
    Grothey, A.
    Sargent, D. J.
    Berlin, J. D.
    Kabbinavar, F. F.
    Dong, W.
    Kozloff, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Treatment center (TC) variability in survival of patients (pts) with colorectal cancer (mCRC) treated with bevacizumab (BV): A subanalysis from the BRiTE Observational Study (OCS)
    Barron, H. V.
    Purdie, D. M.
    Feng, S.
    Sing, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)
    Bekaii-Saab, T. S.
    Bendell, J. C.
    Cohn, A. L.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345